Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

PURPOSE: Conventional chemotherapy has limited activity in patients with breast cancer and brain metastases (BCBM). Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 inhibitor, was designed using advanced polymer technology to preferentially accumulate in tumor tissue including brain meta...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Breast Cancer Res Treat
Hlavní autoři: Cortés, Javier, Rugo, Hope S., Awada, Ahmad, Twelves, Chris, Perez, Edith A., Im, Seock–Ah, Gómez-Pardo, Patricia, Schwartzberg, Lee S., Diéras, Veronique, Yardley, Denise A., Potter, David A., Mailliez, Audrey, Moreno-Aspitia, Alvaro, Ahn, Jin-Seok, Zhao, Carol, Hoch, Ute, Tagliaferri, Mary, Hannah, Alison L., O’Shaughnessy, Joyce
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2017
Témata:
Clinical Trial
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5543189/
https://ncbi.nlm.nih.gov/pubmed/28612225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4304-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky